

FEB 10 1969

UNIVERSITY OF VIRGINIA  
SCHOOL OF MEDICINE  
CHARLOTTESVILLE, VIRGINIA 22901

DEPARTMENT OF PREVENTIVE MEDICINE

February 7, 1969

Dr. Joshua Lederberg  
Department of Genetics  
Stanford University School of Medicine  
Palo Alto, California 94304

DRUG TESTING POLICY DILEMMAS

I was very pleased to receive your letter. I realize that you are recognized as a spokesman for science in the United States, and it is a pleasure to forward this information to you. Please use it in any way you see fit without acknowledging me (the heat is already unbearable), and do not hesitate to call on me if I can be of help in either documenting or elaborating these points. Your letter requests reprints of my articles on this subject, which are enclosed. You have raised four points, each of which is answered separately.

- I. Licensing to Use Drugs
- II. DMSO
- III. Immunosuppressives
- IV. Stalling for Time in Drug Disaster

I hope some of these comments are of interest to you, and may help you in preparing your column. I wish to call your attention to a further topic which I think is of great concern:

V. The Role of the National Institutes of Health in Drug Testing

This is a crucial policy area, and should be of great concern to all biologic scientists because of the key role of the National Institutes of Health in funding biomedical research. Don't hesitate to call on me if I can be of further service.

Best wishes,

*William M O'Brien*

William M. O'Brien, M.D.  
Associate Professor

WMO'B/mh

*It is a personal opinion on a moral matter -  
please treat in confidence.*